Clinical Trial Update: Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]

View source ↗

Summary

Phase 1 study evaluating idelalisib in combination with various chemotherapeutic, immunomodulatory agents, and anti-CD20 antibody in relapsed or refractory indo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Indolent Non-hodgkin Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Idelalisib (idelalisib)

Snippet

Sponsor: Gilead Sciences | Conditions: Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Status: COMPLETED | Results posted: 2021-03-18